What's in Sanofi S.A.'s pipeline?

Sanofi S.A. has 441 drugs in our index: 155 marketed, 0 filed, 141 in Phase 3, 69 in Phase 2, 72 in Phase 1.

Which companies overlap with Sanofi S.A.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Merck Sharp & Dohme LLC, Pfizer, AstraZeneca, Novartis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sanofi.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Sanofi S.A. — Portfolio Competitive Intelligence Brief

Sanofi S.A. (SNY) pipeline: 155 marketed, 0 filed, 141 Phase 3, 69 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

SNY (NASDAQ) 155 marketed 0 filed 141 Phase 3 69 Phase 2 72 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Osteobios	CALCITONIN	marketed	Calcitonin [EPC]	calcitonin receptor	Metabolic	2025-01-01
Neogaa	AVALGLUCOSIDASE ALFA	marketed	Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]		Metabolic	2021-01-01
Fexinidazole	FEXINIDAZOLE	marketed	Nitroimidazole Antimicrobial [EPC]		Hematology	2021-01-01
Adlyxin	LIXISENATIDE	marketed	Insulin Analog [EPC]	Glucagon-like peptide 1 receptor	Metabolic	2016-01-01
Praluent	ALIROCUMAB	marketed	PCSK9 Inhibitor [EPC]	Proprotein convertase subtilisin/kexin type 9	Metabolic	2015-01-01
Cerdelga	ELIGLUSTAT	marketed	Glucosylceramide Synthase Inhibitor [EPC]	Ceramide glucosyltransferase	Metabolic	2014-01-01
Aubagio	TERIFLUNOMIDE	marketed	Pyrimidine Synthesis Inhibitor [EPC]	dihydroorotate dehydrogenase	Immunology	2012-01-01
Caprelsa	VANDETANIB	marketed	Kinase Inhibitor [EPC]	Receptor-interacting serine/threonine-protein kinase 2	Oncology	2011-01-01
Multaq	DRONEDARONE	marketed	Antiarrhythmic [EPC]	Potassium voltage-gated channel subfamily KQT member 2	Cardiovascular	2009-01-01
Mozobil	plerixafor	marketed	Hematopoietic Stem Cell Mobilizer [EPC]	C-C chemokine receptor type 2	Oncology	2008-01-01
Renvela	SEVELAMER CARBONATE	marketed	Phosphate Binder		Hematology	2007-01-01
Xyzal	LEVOCETIRIZINE	marketed	Histamine-1 Receptor Antagonist	Histamine H1 receptor	Immunology	2007-01-01

Therapeutic area mix

Diabetes · 49
Oncology · 39
Cardiovascular · 32
Immunology · 24
Other · 19
Metabolic · 16
Immunology / Infectious Disease · 9
Hematology · 6
Infectious Disease · 6
Dermatology · 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2031-08-07 — Taxotere · 10842770 · Formulation · US
2033-09-30 — Taxotere · 9308195 · Formulation · US
2033-09-30 — Taxotere · 9763880 · Method of Use · US
2033-09-30 — Taxotere · 8940786 · Formulation · US
2036-03-14 — Taxotere · 10398785 · Formulation · US
2036-05-16 — Taxotere · 12090135 · Formulation · US
2036-05-16 — Taxotere · 11419842 · Formulation · US
2036-05-16 — Taxotere · 12090134 · Formulation · US

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 32 shared drug classes
Merck Sharp & Dohme LLC · 25 shared drug classes
Pfizer · 19 shared drug classes
AstraZeneca · 18 shared drug classes
Novartis · 15 shared drug classes
· 14 shared drug classes
Eli Lilly and Company · 14 shared drug classes
Organon and Co · 12 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sanofi S.A.:

Cite this brief

Drug Landscape (2026). Sanofi S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sanofi. Accessed 2026-05-13.